If you were an adult woman in the early 2000s, there is a decent chance
you heard some version of this: hormone replacement therapy causes
breast cancer and heart attacks.
That message did not come out of
nowhere. It came from one of the most influential women’s-health studies
ever conducted—the Women’s Health Initiative, or WHI.
The problem is not that the WHI was a bad study. It was an enormously
important study.
The problem is what happened when a complicated study became a very
simple headline.
First: what was the Women’s Health Initiative actually studying?
The WHI hormone trials were designed largely to answer a question that
was very popular at the time: could menopausal hormone therapy prevent
chronic diseases such as cardiovascular disease in postmenopausal women?
That is important because it is not quite the same question as:
“Is hormone therapy reasonable for a healthy 51-year-old who just
entered menopause and is waking up drenched in sweat every night?”
Women enrolled in the WHI hormone trials were between 50 and 79, with an
average age of approximately 63—considerably older than the average age
of natural menopause.
Women with a uterus received oral conjugated equine estrogen plus
medroxyprogesterone acetate. Women who had undergone hysterectomy were
studied separately and received conjugated equine estrogen alone.
Translation:
WHI did not test every estrogen, every progesterone, every route of
administration or every woman at every age.
It studied specific regimens in a population that included many women
who were substantially older than patients who typically begin
hormone therapy today for menopause symptoms.
Then 2002 happened.
The estrogen-plus-progestin portion of WHI was stopped early after
investigators found that the overall pattern of risks and benefits did
not support using that regimen for chronic-disease prevention.
There were increases in outcomes including breast cancer, coronary
events, stroke and venous thromboembolism, along with benefits such as
fewer fractures.
The message that reached much of the public was considerably less
nuanced:
Prescribing fell dramatically. Women discontinued therapy. Clinicians
became understandably hesitant.
And for years, many women with substantial menopause symptoms avoided
treatment because an individualized risk conversation had essentially
become a yes-or-no question.
Except the estrogen-only trial didn’t tell the same story.
This is one of the details lost when we simply say,
“the WHI showed hormones cause breast cancer.”
It did not show one universal breast-cancer effect across both hormone
trials.
In long-term randomized follow-up, women with prior hysterectomy who had
been assigned conjugated equine estrogen alone had lower breast-cancer
incidence and lower breast-cancer mortality than women assigned placebo.
In contrast, the estrogen-plus-medroxyprogesterone group showed an
increase in breast-cancer incidence in long-term follow-up.
That does not mean estrogen is an anti-cancer medication or that it can
be prescribed indiscriminately.
It means something much more useful:
the formulation matters.
Timing matters too.
As investigators continued analyzing WHI data, it became increasingly
clear that age and time since menopause matter when evaluating hormone
therapy.
Modern menopause guidance generally considers the benefit-risk balance
most favorable for appropriately selected symptomatic women who are
younger than 60 or within approximately 10 years of menopause onset,
assuming they do not have contraindications.
Starting systemic hormone therapy at 51 is not biologically identical
to initiating it for the first time at 72.
So is hormone therapy safe?
I don’t love that question because almost nothing useful in medicine is
simply “safe” or “unsafe.”
The clinically useful question is:
using this hormone, at this dose and by this route—what is the balance
of benefit and risk?
For healthy women near the menopause transition who have bothersome hot
flashes or night sweats and do not have contraindications, hormone
therapy remains the most effective treatment for vasomotor symptoms.
Hormone therapy also helps prevent bone loss while it is being used.
Route matters: swallowing estrogen is not the same as wearing it.
Oral estrogen passes through the liver before reaching systemic
circulation. Transdermal estrogen—a patch, gel or spray—is absorbed
through the skin and avoids the same first-pass hepatic exposure.
Observational data suggest transdermal estrogen may carry less venous
thromboembolism risk than oral estrogen, although route comparisons have
limitations.
Again:
“estrogen” is not one single exposure.
Progesterone is not the same thing as every progestin.
A woman with an intact uterus who receives systemic estrogen generally
also needs adequate endometrial protection.
In WHI, the combination arm used
medroxyprogesterone acetate, a synthetic progestin.
Today, clinicians may also use
micronized progesterone, which is chemically identical
to endogenous human progesterone.
Different progestogens may have different biological and clinical
effects.
Better is not the same thing as magical.
Now let’s clean up the word “bioidentical.”
“Bioidentical” simply means the hormone molecule has the same chemical
structure as the hormone produced by the human body.
Estradiol can be bioidentical.
Micronized progesterone can be bioidentical.
And bioidentical hormones can be available as commercially manufactured
products or through a compounding pharmacy.
Commercial formulations
Available in established strengths and delivery systems such as
patches, gels, capsules and tablets. For many patients, one of those
options fits beautifully.
Compounded formulations
Allow a prescriber and compounding pharmacy to create an
individualized strength, combination or dosage form when standard
commercial choices do not fit the patient’s treatment plan.
The useful distinction
The conversation should not be “bioidentical versus prescription.”
Both approaches are prescription medicine. The question is which
formulation, dose and route make sense for the individual patient.
Where compounded hormones can be especially useful
Bodies do not always cooperate with the handful of dose increments
available in a commercially manufactured medication.
One patient may need a strength between two standard doses. Another may
tolerate one delivery system poorly. Someone else may need a specific
ingredient avoided or a formulation adjusted around an individual
treatment plan.
That is where compounding can be genuinely useful:
it gives us another way to personalize the prescription.
Personalized does not mean we ignore evidence or normal physiologic
targets. It means we can sometimes tailor the medication more precisely
when commercially available choices do not fit well.
This is the part that often gets lost.
The value of compounding is not that the medication becomes magically
“more natural.” The value is flexibility.
Different dose. Different delivery system. Different combination when
clinically appropriate. A prescription built around the patient
instead of forcing every patient into the same few boxes.
Bioidentical versus synthetic is not really a winner-versus-loser question.
Some synthetic hormones have excellent evidence and decades of clinical
use.
Bioidentical estradiol and progesterone also offer useful options and
are commonly used in modern menopause care.
What matters clinically is not whether the word
natural sounds nicer.
It is the actual molecule, dose, route, indication, patient history and
treatment goal.
What changed recently?
In February 2026, the FDA approved labeling changes to six menopausal
hormone-therapy products that removed cardiovascular disease,
breast-cancer and probable-dementia statements from the boxed warning.
That is a significant shift in the way risk is being communicated.
It does not mean every woman should take hormones.
It does mean the conversation has finally become more precise than the
message many women heard twenty years ago.
What the evidence actually allows us to say
It remains the most effective treatment for bothersome menopausal
vasomotor symptoms and is effective for prevention of bone loss
while used.
Benefit and risk are different for someone starting treatment near
menopause than for someone initiating systemic therapy decades later.
Estrogen alone and estrogen combined with different progestogens
should not be treated as identical exposures.
Oral and transdermal estrogen are metabolized differently and can
have different clinical considerations.
Commercial and compounded formulations both give clinicians tools
for building a treatment plan around the individual patient.
The conversation I wish women had been given from the beginning
Menopause is not a hormone-deficiency disease that every woman must
medicate.
It is also not a test of character where you earn extra credit for
suffering through severe symptoms without treatment.
Some women barely notice the transition. Others stop sleeping, develop
significant vasomotor symptoms, experience painful genitourinary
changes, lose sexual function, struggle with mood or cognitive
complaints, or simply stop feeling like themselves.
Those women deserve a serious conversation about their options.
The goal is to stop frightening appropriate women away from them—and to
stop pretending there is one correct formulation for every woman.
That middle ground is less dramatic.
It is also much closer to good medicine.
Want to read the evidence yourself?
The Menopause Society — 2022 Hormone Therapy Position Statement
Evidence-based guidance regarding hormone-therapy benefits, risks,
timing, route and individualization.
Manson et al. — Women’s Health Initiative Randomized Trials and Clinical Practice, JAMA 2024
Contemporary reassessment of WHI findings and their appropriate
clinical interpretation.
Chlebowski et al. — Menopausal Hormone Therapy and Breast Cancer, JAMA 2020
Long-term randomized follow-up examining breast-cancer incidence
and mortality in the WHI hormone trials.
The Menopause Society — Hormone Therapy
Patient-level explanation of contemporary hormone-therapy choices
and bioidentical formulations.
FDA — 2026 Menopausal Hormone Therapy Labeling Changes
February 2026 regulatory update on menopausal hormone-therapy
labeling.
